Commission on Cancer Quality Measure for Omission of Sentinel Lymph Node Biopsy (SNB) in Women Age 70 or Older with Hormone Receptor-Positive (HR+) Invasive Breast Cancer (IBC) Undergoing Breast-Conserving Surgery (BCS): Review of Historical Performance.
Feb 21, 2026DOI: 10.1245/s10434-026-19222-yJournal ArticleASO
Written by: Gabrielle N YeeShelley HwangLee G WilkeLaura M FreedmanAnthony J FroixEmily RayKristine KuchtaLaura EldridgeKatharine A Yao
BACKGROUND: In 2025, the Commission on Cancer (CoC) issued a quality measure recommending omission of sentinel node biopsy (SNB) in women 70 and over with cT1N0, hormone receptor positive (HR+), HER2neu negative invasive breast cancer undergoing breast conserving surgery. We examined historical performance of this measure.METHODS: Trends in omission of SNB and estimated performance rates (EPR) by facility (the proportion of patients in whom SNB was omitted at a facility) were examined from 2012-2023. Multivariate analysis demonstrated facility factors most strongly associated with median compliance rate of 25%.RESULTS: A total of 185,859 patients from the National Cancer Data Base (NCDB) met the aforementioned inclusion criteria. From 2012-2023, SNB was omitted in 43,513 (23.4%) of eligible patients. SNB omission rates were 14% in 2012 versus 44% in 2023. An EPR of 30% was achieved by 655 (52.9%) CoC facilities, 40% by 516 (41.9%) facilities, 50% by 393 (31.7%) facilities, 60% by 278 (22.5%) facilities, 70% by 155 (12.5%) facilities, and 80% by only 85 (6.9%) facilities from 2021-2023. Facilities with > 50% private insurance (OR 1.7, 95% CI:1.23-2.34), academic/teaching designation (OR 2.12, 95% CI:1.36-3.3), high volume (> 250 annual cases) (OR 2.07, 95% CI:1.35-3.18) and in certain census areas of the country were significantly associated with higher likelihood of achieving 25% EPR, the median EPR amongst all site, on multivariate analysis (p < 0.05).CONCLUSION: SNB was omitted on less than half of eligible HR+, HER2neu negative early-stage breast cancer patients over age 70 in 2023, indicating an opportunity for quality improvement.
KY
Dr. Katharine Yao
Surgery · Breast Surgical OncologyEndeavor Healthkatharine